Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

ABSTRACT:

Background

The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of latent infection. We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency.

Methods

In a study of 16 HIV-infected, aviremic individuals, we measured resting CD4+ T cell-associated HIV RNA ex vivo and in vivo following a single exposure to VOR, and then in vivo after a pair of doses separated by 48 or 72 hours, and finally following a series of 10 doses given at 72-hour intervals.

Results

Serial VOR exposures separated by 72 hours most often resul

SUBMITTER: Archin NM 

PROVIDER: S-EPMC5531421 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature